Our legislative and regulatory priorities are guided by our vision to end polycystic kidney disease. All policy priorities must meet our four core standards:
- Increase funding for PKD research to make available new treatments to patients.
- Ensure that PKD patients receive adequate, appropriate, affordable and sustained access to health care throughout the course of life.
- Influence and improve regulatory processes to ensure PKD therapies are produced efficiently and that they are safe, effective and available to all PKD patients.
- Engage and empower the patient voice in policymaking, drug development and regulatory decision-making.